Pharma Q1 Results Preview - Recovery In Chronic, Non-Covid-Acute Segments To Drive Growth: KRChoskey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Pharma companies are expected to continue their strong performance in Q1 FY22 due to low base effect YoY.
Higher demand for acute therapy products including for Covid-19 treatment medicines, other anti-infectives, analgesics, vitamins and gastro products, and recovering demand for chronic segments such as cardiology, will drive growth in domestic formulations side; while continued increased competition in the U.S. is likely to impact sales growth, partially.
For Q1 FY22, we expect our coverage universe to post 11.2% YoY (+4.1% QoQ) growth in sales.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.